HRP20050788A2 - Use of isoquinoline derivatives for treating cancer and map kinase related diseases - Google Patents
Use of isoquinoline derivatives for treating cancer and map kinase related diseasesInfo
- Publication number
- HRP20050788A2 HRP20050788A2 HR20050788A HRP20050788A HRP20050788A2 HR P20050788 A2 HRP20050788 A2 HR P20050788A2 HR 20050788 A HR20050788 A HR 20050788A HR P20050788 A HRP20050788 A HR P20050788A HR P20050788 A2 HRP20050788 A2 HR P20050788A2
- Authority
- HR
- Croatia
- Prior art keywords
- map kinase
- treating cancer
- related diseases
- isoquinoline derivatives
- kinase related
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45362403P | 2003-03-11 | 2003-03-11 | |
| PCT/EP2004/002460 WO2004080464A1 (en) | 2003-03-11 | 2004-03-10 | Use of isoquinoline derivatives for treating cancer and map kinase related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050788A2 true HRP20050788A2 (en) | 2006-12-31 |
Family
ID=32990797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050788A HRP20050788A2 (en) | 2003-03-11 | 2004-03-10 | Use of isoquinoline derivatives for treating cancer and map kinase related diseases |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1603566B1 (https=) |
| JP (1) | JP2006519807A (https=) |
| KR (1) | KR20050108383A (https=) |
| CN (1) | CN1758910A (https=) |
| AT (1) | ATE421324T1 (https=) |
| AU (1) | AU2004218914A1 (https=) |
| BR (1) | BRPI0408257A (https=) |
| CA (1) | CA2518530A1 (https=) |
| DE (1) | DE602004019193D1 (https=) |
| ES (1) | ES2318276T3 (https=) |
| HR (1) | HRP20050788A2 (https=) |
| IS (1) | IS8064A (https=) |
| MA (1) | MA27724A1 (https=) |
| MX (1) | MXPA05009687A (https=) |
| NO (1) | NO20054647L (https=) |
| PL (1) | PL1603566T3 (https=) |
| PT (1) | PT1603566E (https=) |
| RU (1) | RU2325159C2 (https=) |
| TN (1) | TNSN05223A1 (https=) |
| TW (1) | TW200501955A (https=) |
| WO (1) | WO2004080464A1 (https=) |
| ZA (1) | ZA200506571B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2526285A1 (en) | 2003-05-15 | 2004-12-23 | Arqule, Inc. | Inhibitors of p38 and methods of using the same |
| AR045944A1 (es) * | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| EP2258704A1 (en) | 2004-10-19 | 2010-12-08 | ArQule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| EP1863491A1 (en) * | 2005-02-25 | 2007-12-12 | Novartis AG | Pharmaceutical combination of bcr-abl and raf inhibitors |
| RS52241B (sr) * | 2005-07-26 | 2012-10-31 | Sanofi | Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze |
| EP2046753A2 (en) | 2006-07-06 | 2009-04-15 | Brystol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| JP2009077712A (ja) * | 2007-09-11 | 2009-04-16 | F Hoffmann La Roche Ag | Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験 |
| US8926561B2 (en) | 2009-07-30 | 2015-01-06 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| BR112012022801B8 (pt) * | 2010-03-09 | 2019-10-29 | Dana Farber Cancer Inst Inc | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer |
| US9056855B2 (en) * | 2010-10-28 | 2015-06-16 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| CN103435430B (zh) * | 2013-08-08 | 2015-02-18 | 四川大学 | 一种还原酰胺类化合物的方法 |
| KR102119943B1 (ko) | 2018-05-23 | 2020-06-05 | 주식회사 포스코 | 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치 |
| CA3104808A1 (en) * | 2018-07-02 | 2020-01-09 | Ecole Polytechnique Federale De Lausanne (Epfl) | Lactate enhancing compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| PT1107964E (pt) * | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| DOP2000000070A (es) * | 1999-09-28 | 2002-02-28 | Bayer Healthcare Llc | Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis |
| PT1254138E (pt) * | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
| US20030078271A1 (en) * | 2001-01-31 | 2003-04-24 | Blackburn Thomas P. | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| ATE497603T1 (de) * | 2001-03-02 | 2011-02-15 | Gpc Biotech Ag | Drei-hybrid-assaysystem |
| WO2003059354A2 (en) * | 2001-12-21 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| US7220775B2 (en) * | 2002-08-07 | 2007-05-22 | H. Lundbeck A/S | Compound useful for the treatment of neuropathic pain |
-
2004
- 2004-03-10 CA CA002518530A patent/CA2518530A1/en not_active Abandoned
- 2004-03-10 BR BRPI0408257-5A patent/BRPI0408257A/pt not_active IP Right Cessation
- 2004-03-10 PL PL04718960T patent/PL1603566T3/pl unknown
- 2004-03-10 EP EP04718960A patent/EP1603566B1/en not_active Expired - Lifetime
- 2004-03-10 HR HR20050788A patent/HRP20050788A2/xx not_active Application Discontinuation
- 2004-03-10 PT PT04718960T patent/PT1603566E/pt unknown
- 2004-03-10 ES ES04718960T patent/ES2318276T3/es not_active Expired - Lifetime
- 2004-03-10 JP JP2006504625A patent/JP2006519807A/ja active Pending
- 2004-03-10 DE DE602004019193T patent/DE602004019193D1/de not_active Expired - Lifetime
- 2004-03-10 KR KR1020057016936A patent/KR20050108383A/ko not_active Ceased
- 2004-03-10 AU AU2004218914A patent/AU2004218914A1/en not_active Abandoned
- 2004-03-10 RU RU2005131168/04A patent/RU2325159C2/ru not_active IP Right Cessation
- 2004-03-10 CN CNA2004800065706A patent/CN1758910A/zh active Pending
- 2004-03-10 AT AT04718960T patent/ATE421324T1/de active
- 2004-03-10 WO PCT/EP2004/002460 patent/WO2004080464A1/en not_active Ceased
- 2004-03-10 MX MXPA05009687A patent/MXPA05009687A/es active IP Right Grant
- 2004-03-10 TW TW093106341A patent/TW200501955A/zh unknown
-
2005
- 2005-08-17 ZA ZA200506571A patent/ZA200506571B/en unknown
- 2005-09-09 TN TNP2005000223A patent/TNSN05223A1/en unknown
- 2005-09-23 MA MA28511A patent/MA27724A1/fr unknown
- 2005-10-10 NO NO20054647A patent/NO20054647L/no not_active Application Discontinuation
- 2005-10-10 IS IS8064A patent/IS8064A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE421324T1 (de) | 2009-02-15 |
| RU2005131168A (ru) | 2006-05-27 |
| EP1603566B1 (en) | 2009-01-21 |
| TNSN05223A1 (en) | 2007-06-11 |
| BRPI0408257A (pt) | 2006-03-07 |
| TW200501955A (en) | 2005-01-16 |
| ZA200506571B (en) | 2006-07-26 |
| EP1603566A1 (en) | 2005-12-14 |
| JP2006519807A (ja) | 2006-08-31 |
| AU2004218914A1 (en) | 2004-09-23 |
| PT1603566E (pt) | 2009-04-27 |
| DE602004019193D1 (de) | 2009-03-12 |
| KR20050108383A (ko) | 2005-11-16 |
| IS8064A (is) | 2005-10-10 |
| NO20054647L (no) | 2005-12-09 |
| PL1603566T3 (pl) | 2009-07-31 |
| MXPA05009687A (es) | 2005-10-20 |
| NO20054647D0 (no) | 2005-10-10 |
| WO2004080464A1 (en) | 2004-09-23 |
| RU2325159C2 (ru) | 2008-05-27 |
| ES2318276T3 (es) | 2009-05-01 |
| CA2518530A1 (en) | 2004-09-23 |
| CN1758910A (zh) | 2006-04-12 |
| MA27724A1 (fr) | 2006-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050788A2 (en) | Use of isoquinoline derivatives for treating cancer and map kinase related diseases | |
| TNSN06093A1 (en) | 1,4- disubstituted isoquinoline derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | |
| UA96565C2 (ru) | Пиридильные ингибиторы хеджхоговской передачи сигнала | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| EA200801037A1 (ru) | Ингибиторы фосфатидилинозит-3-киназы и способы их применения | |
| EA200700321A1 (ru) | Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы | |
| HRP20050041B1 (hr) | UPOTREBA INHIBITORA IκB KINAZE U TERAPIJI BOLOVA | |
| MEP36208A (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers | |
| BRPI0409198A (pt) | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas | |
| NO20060230L (no) | Nye aminobenzofenonforbindelser | |
| CY1105477T1 (el) | Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου | |
| EA201070424A1 (ru) | Хиназолиндионовые производные, их получение и их применения в терапии | |
| EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
| CY1109569T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
| EA200501310A1 (ru) | Производные бензолсульфонамидов, способ их получения и их применение для лечения боли | |
| ATE524181T1 (de) | Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen | |
| EA201990311A1 (ru) | АНТИМЕТАСТАТИЧЕСКИЕ 2H-СЕЛЕНОФЕН[3,2-h]ХРОМЕНЫ, СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ | |
| EA200600992A1 (ru) | Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение | |
| ATE523199T1 (de) | Pyridazinverbindungen und verfahren | |
| ATE406375T1 (de) | Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate | |
| ATE431348T1 (de) | Thiaepothilone zur behandlung von krebserkrankungen | |
| NO20055650D0 (no) | Ruteinum (II)-komplekser for behandling av tumorer | |
| ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| ATE345795T1 (de) | 1-phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivate und verwandte verbindungen als faktor xa inhibitoren zur behandlung von akuten gefässerkrankungen | |
| DE502004008294D1 (de) | Neue makrocyclen zur behandlung von krebserkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080310 Year of fee payment: 5 |
|
| OBST | Application withdrawn |